Huangsheng Tan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Huangsheng Tan has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Chengcai Dai
The Fourth Clinical Medical College Affiliated to Guangzhou University of Traditional Chinese Medicine, China
1 shared publicationJuyi Lai
Shenzhen Traditional Chinese Medicine Hospital, China
1 shared publicationPan Shen
Jiangxi University of Traditional Chinese Medicine
1 shared publication- Shenghua He
The Fourth Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510006, China
1 shared publication Xinhai Gao
The Fourth Clinical Medical College Affiliated to Guangzhou University of Traditional Chinese Medicine, China
1 shared publication- Yuanfei Fu
The Fourth Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510006, China
1 shared publication
Latest Publications
- Open Access
- 20 June 2025
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 53 (6)
Mendelian randomization analysis of gut microbiota-driven immune modulation in rheumatoid arthritis: New mechanistic insights and therapeutic targets
Objective: To explore the complex interactions between gut microbiota and immune cell phenotypes in rheumatoid arthritis development and identify potential therapeutic targets within the gut microbiota–immune cell axis. Methods: We conducted a Mendelian randomization analysis to explore the causal relationship between gut microbiota and rheumatoid arthritis, including the role of immune cell mediators. Sensitivity analyses assessed pleiotropy and heterogeneity, while mediation analysis identified pathways through which immune cells mediate gut microbiota effects on rheumatoid arthritis development. Key microbial taxa and their effects on rheumatoid arthritis were quantified. Results: Our analysis identified 27 gut microbiota taxa significantly associated with rheumatoid arthritis, with Provencibacterium massiliense showing the strongest protective effect (odds ratio = 0.807, 95% confidence interval: 0.700–0.911, P = 0.003). Additionally, 20 immune cell phenotypes with IgD+ CD38dim AC were significantly linked to rheumatoid arthritis (odds ratio = 1.064, 95% confidence interval: 1.027–1.102). Mediation analysis uncovered 13 significant gut microbiota–immune cell pathways, with the UBA8517–CCR2 monocyte pathway mediating 10.1% of the total effect (beta1 = −0.595, beta12 = 0.027, mediation proportion = 10.1%). Conclusion: This study offers novel insights into the gut microbiota–immune cell axis in rheumatoid arthritis, identifying Provencibacterium massiliense , IgD+ CD38dim AC and the UBA8517—CCR2 monocyte pathway as potential therapeutic targets for rheumatoid arthritis treatment.
- 20 June 2025
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 53 (6)
Open AccessMendelian randomization analysis of gut microbiota-driven immune modulation in rheumatoid arthritis: New mechanistic insights and therapeutic targets
Objective: To explore the complex interactions between gut microbiota and immune cell phenotypes in rheumatoid arthritis development and identify potential therapeutic targets within the gut microbiota–immune cell axis. Methods: We conducted a Mendelian randomization analysis to explore the causal relationship between gut microbiota and rheumatoid arthritis, including the role of immune cell mediators. Sensitivity analyses assessed pleiotropy and heterogeneity, while mediation analysis identified pathways through which immune cells mediate gut microbiota effects on rheumatoid arthritis development. Key microbial taxa and their effects on rheumatoid arthritis were quantified. Results: Our analysis identified 27 gut microbiota taxa significantly associated with rheumatoid arthritis, with Provencibacterium massiliense showing the strongest protective effect (odds ratio = 0.807, 95% confidence interval: 0.700–0.911, P = 0.003). Additionally, 20 immune cell phenotypes with IgD+ CD38dim AC were significantly linked to rheumatoid arthritis (odds ratio = 1.064, 95% confidence interval: 1.027–1.102). Mediation analysis uncovered 13 significant gut microbiota–immune cell pathways, with the UBA8517–CCR2 monocyte pathway mediating 10.1% of the total effect (beta1 = −0.595, beta12 = 0.027, mediation proportion = 10.1%). Conclusion: This study offers novel insights into the gut microbiota–immune cell axis in rheumatoid arthritis, identifying Provencibacterium massiliense , IgD+ CD38dim AC and the UBA8517—CCR2 monocyte pathway as potential therapeutic targets for rheumatoid arthritis treatment.